Tag: 200-300

On January 25, 2007, Uchida, Hideharu; Kosuga, Naoto; Satoh, Tsutomu; Hotta, Daido; Kamino, Tomoyuki; Maeda, Yoshitaka; Amano, Ken-Ichi; Akada, Yasushige published a patent.Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of novel 2-(bicyclic heterocyclidene)acetamide derivatives as antagonists of transient receptor potential type 1 (TRPV1). And the patent contained the following:

The title compounds (I) or salts thereof, and solvates of any of them [m, n, p = an integer of 0-2; q = 0, 1; R1 = halo, each (un)substituted hydrocarbyl, heterocyclyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, NH2, HO, CO2H, CONH2, or SO2NH2, C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, NO2; R2 = halo, (un)substituted NH2, hydrocarbyl, or aromatic heterocyclyl, oxo; or two geminal or vicinal R2s together form C2-6 alkylene; R2 and the carbon atom attached to R2 together form a cyclic ring; X1 = O, (un)substituted NH, S, SO, SO2; X2 = CH2, O, (un)substituted NH, S, SO, SO2; Q1 = each (un)substituted heteroaryl, heteroarylalkyl, aryl, or aralkyl; the Cy ring = 5- or 6-membered aryl or heteroaryl; a dotted line represents the condensation of two rings; a wavy line represent E or Z configuration; some exceptions are defined] are prepared These compounds are useful for the treatment or prevention of pains. Thus, tri-Et phosphonoacetate was treated with NaH in THF at ≤20° for 1 h and condensed with 4-chromanone at room temperature overnight to give (E)-(chroman-4-ylidene)acetic acid Et ester which was refluxed in aqueous THF solution containing LiOH and neutralized with 1 N aqueous HCl solution to give (E)-(chroman-4-ylidene)acetic acid (II). II was condensed with 1,4-benzodioxan-6-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 at room temperature overnight to give (E)-2-(chroman-4-ylidene)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acetamide (III). III and (E)-2-(8-trifluoromethyl-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene)-N-(quinoxalin-6-yl)acetamide in vitro showed A2 of ≥100 nM and <100 nM, resp., for antagonizing the capsaicin-induced cellular influx of Ca in CHO cell expressing human TRPV1. Pharmaceutical formulations, e.g. a tablet containing (E)-2-(7-tert-Butylchroman-4-ylidene)-N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide, were prepared The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to capsaicin receptor trpv1 antagonist bicyclic heterocyclideneacetamide preparation, bicyclic heterocyclideneacetamide preparation antagonist transient receptor potential type 1, chromanylideneacetamide benzooxepinylideneacetamide preparation treatment prevention pain, pain treatment prevention bicyclic heterocyclideneacetamide preparation and other aspects.Quality Control of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 4, 1984, Makosza, Mieczyslaw; Winiarski, Jerzy published an article.Quality Control of tert-Butyl 2-(4-nitrophenyl)acetate The title of the article was Reactions of organic anions. Part 110. Vicarious nucleophilic substitution of hydrogen in nitroarenes with α-substituted nitriles and esters. Direct α-cyanoalkylation and α-carbalkoxyalkylation of nitroarenes. And the article contained the following:

Carbanions generated from alkanenitriles bearing α-chloro, α-OR (R = Me, Ph, chlorophenyl) or α-SR (R = Me, Ph, Me2NCS) groups and from aliphatic esters bearing α-SR groups react with mononitroarenes to replace H atoms of the nitroarom. ring ortho or para to the NO2 group with α-cyanoalkyl or α-carbalkoxyalkyl substituents. The nucleophilic replacement of H with such carbanions proceeds faster than substitution of halogen ortho or para to the NO2 group. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Quality Control of tert-Butyl 2-(4-nitrophenyl)acetate

The Article related to vicarious nucleophilic substitution nitroarene, cyanoalkylation nitroarene, carbalkoxyalkylation nitroarene, nitroarene cyanoalkylation carbalkoxyalkylation, alkylation cyano carbalkoxy nitroarene, alkanenitrile chloro oxy thio anion, chloroalkanenitrile anion reaction, oxyalkanenitrile anion reaction, thioalkanenitrile anion reaction and other aspects.Quality Control of tert-Butyl 2-(4-nitrophenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zhang, Xue; Ling, Liang; Luo, Meiming; Zeng, Xiaoming published an article in 2019, the title of the article was Accessing Difluoromethylated and Trifluoromethylated cis-Cycloalkanes and Saturated Heterocycles: Preferential Hydrogen Addition to the Substitution Sites for Dearomatization.Related Products of 141940-37-6 And the article contains the following content:

A straightforward process in which a cyclic (alkyl)(amino)carbene/Rh catalyst system facilitates preferential addition of hydrogen to substitution sites of difluoromethylated and trifluoromethylated arenes and heteroarenes, leading to dearomative reduction was reported. This strategy enabled diastereoselective synthesis of cis-difluoromethylated and cis-trifluoromethylated cycloalkanes such as I [R = 2-COMe, 4-pyrazolyl, 3-OTBS, etc.; R1 = CF2H, CF3] and saturated heterocycles, e.g. II, and even allowed formation of all-cis multi-trifluoromethylated cyclic products with a defined equatorial orientation of the di- and trifluoromethyl groups. Deuterium-labeling studies indicated that hydrogen preferentially attacked substitution sites of planar arenes, resulting in dearomatization, possibly with heterogeneous Rh as reactive species, followed by either reversible or irreversible hydrogen addition to nonsubstitution sites. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to difluoromethyl cis cycloalkane saturated heterocycle diastereoselective preparation, arene heteroarene cycloalkyl amino carbene rhodium catalyst dearomative reduction, trifluoromethyl cis cycloalkane saturated heterocycle diastereoselective preparation, heteroarene arene cycloalkyl amino carbene rhodium catalyst dearomative reduction and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 3, 2019, Bhardwaj, Monika; Rasool, Faheem; Tatina, Madhu Babu; Mukherjee, Debaraj published an article.Computed Properties of 2873-29-2 The title of the article was Construction of Fused Oxabicyclic Scaffolds from Glycals and Styrenes via One-Pot Domino Transformations. And the article contained the following:

Glycals underwent diastereoselective cascade ring opening and cyclocondensation reactions with styrenes in the presence of TfOH in CH2Cl2 to yield arylcyclopentenofurans such as I. When either benzene or toluene was used as solvent, glycals underwent diastereoselective cascade Ferrier C-glycosylation and double Friedel-Crafts reactions with styrenes in the presence of TfOH to yield arylnaphthopyrans (oxadecalins) such as II. The mechanism of the reaction of triacetoxy-D-glucal with styrene in benzene was studied by isolation of intermediates and by determination of the deuterium kinetic isotope effect which provided evidence for the C-glycosylation as the slow step in the reaction. A mechanism for the reactions is proposed. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Computed Properties of 2873-29-2

The Article related to arylcyclopentenofuran arylnaphthopyran diastereoselective nonracemic preparation, triflic acid catalyst ring opening cyclocondensation glycosylation styrene glycal, stereoselective tandem ring opening cyclocondensation styrene glycal dichloromethane solvent, tandem ferrier glycosylation friedel crafts reaction styrene glycal arene and other aspects.Computed Properties of 2873-29-2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 24, 1993, Gilbert, Kevin; Williams, Peter D.; Hobbs, Doug W.; Evans, Ben E.; Veber, Daniel F. published a patent.Electric Literature of 53838-27-0 The title of the patent was Preparation of hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives as oxytocin and vasopressin antagonists. And the patent contained the following:

Title compounds [I; R = substituted (unsaturated) 5- or 6-membered heterocyclyl containing 1-3 of N, O, or S], were prepared as oxytocin antagonists (no data). Thus, indene in THF was treated with LiN(SiMe3)2 and then with (ClCH2CH2)2NCO2CMe3 (preparation given) to give 1′-(tert-butoxycarbonyl)spiro(indene-1,4-piperidine), which was deprotected and acylated with (+)-10-comphorsulfonyl chloride followed by oximation and reduction with H2/Raney Ni to give endo-I (R = NH2). This was treated with 4-nitrophenyl chloroformate/Et3N, then with H-His-OMe.2HCl/Et3N, and finally with NaH in EtOH to give I (R = Q). The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Electric Literature of 53838-27-0

The Article related to bicycloheptylmethylsulfonylspiroindanepiperidine oxytocin antagonist, spiroindanepiperidine bicycloheptylmethylsulfonyl preparation, preterm labor prevention spiroindenepiperidine, dysmenorrhea treatment spiroindanepiperidine, vasopressin antagonist spiroindanepiperidine, hydantoin spiroindanylcamphorsulfonyl oxytocin antagonist and other aspects.Electric Literature of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 3, 2006, Sekiguchi, Yoshinori; Kuwada, Takeshi; Hayashi, Masato; Nozawa, Dai; Amada, Yuri; Shibata, Tsuyoshi; Yamamoto, Shuji; Ohta, Hiroshi; Okubo, Taketoshi; Koami, Takeshi published a patent.Related Products of 141940-37-6 The title of the patent was Preparation of 1,3-dihydro-2H-indol-2-one compounds and pyrrolidin-2-one compound fused with aromatic heterocycle as antagonists of arginine-vasopressin V1b receptor. And the patent contained the following:

The title compounds [I; ring A = each (un)substituted C6-14 aryl or aromatic heterocyclyl; P = a single bond, C1-5 alkylene; Q = each (un)substituted C6-14 aryl or aromatic heterocyclyl, Q1; RD and RE at 2 and 3 or 3 and 4 positions together form (un)substituted C1-3 alkylenedioxy, (CH2)m-O, N-(un)substituted (CH2)m-NH or NH-(CH2)m, (CH2)m-S, O-(CH2)m-S, or S-(CH2)m-S (m = 2-4); R5 = Q2, Q3, etc.; R6 = H, halo, (un)substituted HO; R7 = H, halo, (un)substituted SH; or R6 and R7 together represent oxo; R9 = each (un)substituted OH, SH or NH2; R33 = H, (un)substituted C1-5 alkyl, C3-8 cycloalkyl, C1-5 alkoxycarbonyl, C6-14 aryl, heterocyclyl; RA, RB, RC = H, halo, NO2, NH2, hydroxyamino, C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, etc.] or pharmacol. acceptable salts thereof are prepared These compounds are highly selectively antagonistic to arginine-vasopressin V1b receptor over arginine-vasopressin V1a receptor and arginine-vasopressin V2 receptor, have high metabolic stabilities and show favorable migration into the brain and high concentrations in the plasma. They provide drugs which are efficacious against pathol. conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, they provide drugs which have a therapeutic or preventive effect on depression, anxiety, Alzheimer’s disease, Parkinson’s disease, Huntington’s chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. Thus, reductive amination of (4R)-1-((3R)-5-Chloro-3-[2-methoxy-5-(2-oxoethyl)phenyl]-1-([4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-L-prolinamide with piperidine using sodium triacetoxyborohydride in the presence of acetic acid din a mixture of THF and CHCl3 gave (+)-(4R)-1-[5-Chloro-3-[5-[2-(dimethylamino)ethyl]-2-methoxyphenyl]-1-[[4-methoxy-2-(trifluoromethoxy)phenyl]sulfonyl]-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-L-prolinamide (II). II inhibited the binding of [3H](Arg8)vasopressin to human arginine vasopressin V1b, V1a, and V2 receptor with IC50 of 0.32, 102, and 5,050, nM, resp. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to phenylsulfonylindolylprolinamide preparation antagonist arginine vasopressin v1b receptor, dihydroindolone preparation antagonist arginine vasopressin v1b receptor, pyrrolidinone fused heterocycle preparation antagonist arginine vasopressin v1b receptor, depression anxiety alzheimer disease treatment dihydroindolone preparation and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 4, 2000, Suzuki, Nobuhiro; Takekawa, Shiro; Kubo, Keiji; Imaeda, Yasuhiro published a patent.Product Details of 29704-38-9 The title of the patent was Preparation of imidazole derivatives as gonadotropin-releasing hormone antagonists. And the patent contained the following:

Claimed are gonadotropin-releasing hormone (GnRH) antagonists containing the title compounds [I; ring A = (un)substituted Ph; ring B = (un)substituted cyclic group; R4 , R6 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, (un)substituted C7-13 aralkyl, C2-7 alkoxycarbonyl; R5 = H, halo, (un)substituted C1-6 alkyl, C1-6 alkoxy, C2-7 alkoxycarbonyl, etc.; X = bond, C1-6 alkylene, C2-6 alkenylene, C1-6 alkylene-NHCO, C1-6 alkylene-O2NH; Y = CO, SO2, NHCO, C1-6 alkylene-CO, C2-6 alkylene-CO, C1-6 alkylene] or pharmacol. acceptable salts thereof. These compounds are useful for the treatment or prevention of gonadotropin-releasing hormone-related diseases such as sex hormone-dependent cancer, prostate cancer, uterine cancer, breast cancer, prostatic hypertrophy, true precocious puberty, endometriosis, hysteromyoma, pregnancy regulators, and menstruation regulators. Thus, 5-amino-2-(4-methoxyphenyl)benzimidazole was condensed with 4-pyrrolidinobenzoic acid using di-Et cyanophosphate in the presence of Et3N and 4-dimethylaminopyridine in DMF at room temperature for 1 h to give 41% 2-(4-methoxyphenyl)-5-((4-pyrrolidinobenzoyl)amino)benzimidazole (II). II in vitro showed IC50 of μg/mL for inhibiting the binding of [125I]leuprolelin to a membrane sample of CHO cell expressing human GnRH receptor. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Product Details of 29704-38-9

The Article related to antitumor agents, benign prostatic hyperplasia, endometriosis, mammary gland neoplasm, menstruation (regulators), myoma (hysteromyoma), neoplasm (sex hormone-dependent), precocious puberty (true), pregnancy (regulators), prostate gland neoplasm, uterus neoplasm and other aspects.Product Details of 29704-38-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 4, 1999, Hewawasam, Piyasena; Starrett, John E., Jr.; Swartz, Stephen G. published a patent.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the patent was Preparation of 4-aryl-3-aminoquinoline-2-ones as potassium channel modulators. And the patent contained the following:

The title compounds [I; R, R1 = H, Me; R2-R4 = H, halo, NO2, CF3; R5 = H, alkyl, alkylsulfonyl, etc.; R6 = H, Br, Cl, NO2] which are modulators of the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels such as ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction, and urinary incontinence, were prepared Thus, demethylation of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one (preparation given) with BBr3 in CH2Cl2 afforded 97% I [R1 = H; R2 = R4 = H; R3 = CF3; R5 = H; R6 = Cl; RO = 2-OH] which showed > 150% increase over BK current in controls at 20 μM. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to potassium channel modulator arylaminoquinolinone preparation, quinolinone arylamino preparation potassium channel modulator, ischemia arylaminoquinolinone preparation, stroke arylaminoquinolinone preparation, anticonvulsant arylaminoquinolinone preparation, antiasthmatic arylaminoquinolinone preparation, irritable bowel syndrome arylaminoquinolinone preparation and other aspects.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 1, 2002, Arrhenius, Thomas; Chen, Mi; Cheng, Jie Fei; Huang, Yujin; Nadzan, Alex; Penuliar, Richard; Wallace, David; Zhang, Lin published a patent.HPLC of Formula: 53838-27-0 The title of the patent was Preparation of hydroxyhexafluoropropylazoles, -azines, and alkynes as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators. And the patent contained the following:

Pharmaceutical compositions for inhibiting malonyl-CoA decarboxylase (MCD) comprising ZF2CCWX(AY) [W = (substituted) 5-membered nonaromatic heterocyclyl containing 1 double bond, 6-membered heterocyclyl containing 0-2 double bonds, alkynyl, 5-6 membered heteroaryl; A = O, S, NR3; X = H, CF2Z, CF3; XY = double bond; Z = F, Br, Cl, iodo, CF3], are claimed. Thus, 2-[2-(butylamino)thiazol-5-yl]-1,1,1,3,3,3-hexafluoropropan-2-ol (preparation given) was refluxed 4 h with EtNCO in benzene to give N-butyl-N’-ethyl-N-[5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]thiazol-2-yl]urea. Tested title compounds inhibited MCD with IC50 = 0.024-3.71 μM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).HPLC of Formula: 53838-27-0

The Article related to azole preparation malonyl coa decarboxylase inhibitor, thiazole hexafluorohydroxypropyl acylamino preparation malonyl coa decarboxylase inhibitor, fatty acid glucose metabolism disorder treatment azole, cardiovascular disease treatment azole preparation, angina pectoris treatment azine, obesity treatment alkyne, acidosis treatment azole, cancer treatment azole and other aspects.HPLC of Formula: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 25, 2020, Escobar, Randolph A.; Johannes, Jeffrey W. published an article.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate The title of the article was A Unified and Practical Method for Carbon-Heteroatom Cross-Coupling using Nickel/Photo Dual Catalysis. And the article contained the following:

A general method that allows for C-O, C-N and C-S cross-coupling reactions under one general set of conditions has been described. An energy transfer pathway, in which an iridium photosensitizer produces an excited nickel(II) complex, is responsible for the key reductive elimination step that couples aryl halides RX (R = C6H5, 4-CF3C6H4, 3-pyridyl, etc.; X = Cl, Br, I) to 1° R1CH2OH (R1 = C6H5, 2-thienyl, 3-pyridyl, etc.) and 2° alcs. R2R3CHOH (R2 = Me, (CH2)2CH3, C6H5; R3 = Me; R2R3 = -(CH2)5-, R2R3 = -(CH2)4-, R2R3 = -(CH2)3-), amines R4NH2 (R4 = (CH2)3CH3, C6H5, 2-naphthyl, etc.) and 1-phenylethan-1-amine, thiols R5SH (R5 = C6H5, 2-naphthyl, cyclopentyl, etc.), carbamates R6OC(O)NH2 (R6 = t-Bu, Bn, allyl), and benzenesulfonamide, and is amenable to scale up via a flow app has been discussed. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

The Article related to ether preparation, alc aryl halide cross coupling nickel iridium dual photocatalyst, amine aryl halide cross coupling nickel iridium dual photocatalyst, thiol aryl halide cross coupling nickel iridium dual photocatalyst, carbamate aryl halide cross coupling nickel iridium dual photocatalyst, cross-coupling, dual catalysis, nickel catalysis, photocatalysis and other aspects.Application In Synthesis of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics